Persistent Asset Partners Ltd Has $839,000 Holdings in Humana Inc. (NYSE:HUM)

Key Points

• Persistent Asset Partners Ltd reduced its stake in Humana Inc. by 91.7% in the first quarter, now holding 3,170 shares valued at $839,000.
• Hedge funds have been active around Humana, with Cary Street Partners increasing its stake by 63.9% and new investments from firms like Riverview Trust Co and Garde Capital Inc.
• Analysts have a consensus price target of $281.62 for Humana, with several upgrades and varying ratings from firms such as Morgan Stanley and Raymond James.

Persistent Asset Partners Ltd lessened its position in Humana Inc. (NYSE:HUM - Free Report) by 91.7% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 3,170 shares of the insurance provider's stock after selling 34,990 shares during the period. Persistent Asset Partners Ltd's holdings in Humana were worth $839,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in HUM. Cary Street Partners Investment Advisory LLC boosted its position in shares of Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after buying an additional 46 shares during the last quarter. Riverview Trust Co bought a new stake in Humana during the first quarter worth $34,000. Garde Capital Inc. bought a new stake in Humana during the first quarter worth $36,000. Zions Bancorporation National Association UT bought a new stake in Humana during the first quarter worth $37,000. Finally, Transce3nd LLC bought a new stake in Humana during the fourth quarter worth $38,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HUM. Morgan Stanley dropped their price target on Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a report on Thursday, July 31st. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a report on Thursday, May 1st. Wells Fargo & Company set a $348.00 target price on Humana in a research note on Friday, July 18th. Barclays set a $275.00 target price on Humana and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Finally, Oppenheimer boosted their target price on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Seventeen analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $281.62.

Humana Trading Up 0.2%

HUM opened at $267.19 on Tuesday. The business has a 50 day simple moving average of $238.61 and a two-hundred day simple moving average of $253.70. The firm has a market capitalization of $32.13 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 1.57 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. Humana Inc. has a one year low of $206.87 and a one year high of $382.72.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The company's revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the company earned $6.96 EPS. Analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.